Status:
UNKNOWN
Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Leukemia, Myelomonocytic, Acute
Eligibility:
All Genders
60+ years
Phase:
PHASE1
Brief Summary
After complete remission, elderly AML patients cannot tolerate hematopoietic stem cell transplantation and standard-dose consolidation chemotherapy, and the 5-year survival rate is around 10%. Therefo...
Detailed Description
20 elderly AML patients who achieved complete remission (CR) after induction chemotherapy will be enrolled in this study. Baseline data are collected and informed consents are signed before consolidat...
Eligibility Criteria
Inclusion
- Age ≥60 years
- Patients with primary AML diagnosed in accordance with the "Adult Acute Myeloid Leukemia (Non-Acute Promyelocytic Leukemia) Chinese Diagnosis and Treatment Guidelines (2017 Edition)", who achieved CR after induction chemotherapy
- Normal heart function , Ejection fraction ≥ 50%
- Normal liver function with ALT and AST ≤ 2.5 times the upper limit of normal value, bilirubin ≤ 2 times the upper limit of normal value
- Normal kidney function with blood creatinine ≤ 3.0 mg/dL (≤ 260 µmol/L)
- Voluntarily signed an informed consent.
Exclusion
- Combined with severe infection
- Combined with other malignant tumors
- Other patients deemed unsuitable to be tested by the investigator
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04687657
Start Date
February 1 2021
End Date
June 1 2024
Last Update
August 24 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The first affiliated hospital of Xi'an jiaotong university
Xi’an, Shanxi, China, 710061
2
Xi'anJiaotong University
Xi’an, Shanxi, China, 710061